An explosion in Medicare spending on epilepsy testing resembles a pattern of improper payments for genetic testing that was previously flagged in a 2023 OIG report.

Peters said despite an SSA risk assessment warning of up to 65% chance of catastrophic breach, the data remains in systems without verified security controls.

Biomea Fusion shares spiked on positive 52-week Phase II data for icovamenib in type 2 diabetes. Read why I rate BMEA stock a hold and remain on the sidelines.

Data centres are moving closer to becoming a reality in Alberta, with Pembina Pipeline and partner Kineticor Asset Management ...

The number of international students arriving in the United States this August fell by 19 % compared to the same time last ...

Old school stock pickers were quick to blame the quant funds for triggering outsized share price swings in August. But fund ...